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Thymic stromal lymphopoietin (TSLP) is a cytokine that promotes CD4
 
 
 
 T cell homeostasis. 
We now demonstrate that TSLP is required to mount a normal CD4
 
 
 
 T cell–mediated 
inflammatory response. TSLP acts directly on naive, but not, memory CD4
 
 
 
 T cells, and 
promotes their proliferation in response to antigen. In addition, TSLP exerts an effect 
indirectly through DCs to promote Th2 differentiation of CD4
 
 
 
 T cells. Correspondingly, 
TSLP receptor (TSLPR) knockout (KO) mice exhibit strong Th1 responses, with high levels of 
interleukin (IL)-12, interferon-
 
 
 
, and immunoglobulin (Ig) G2a, but low production of IL-4, 
-5, -10, -13, and IgE; moreover, CD4
 
 
 
 T cells from these animals proliferate less well in 
response to antigen. Furthermore, TSLPR KO mice fail to develop an inflammatory lung 
response to inhaled antigen unless supplemented with wild-type CD4
 
 
 
 T cells. This underscores 
an important role for this cytokine in the development of inflammatory and/or allergic 
responses in vivo.
 
Thymic stromal lymphopoietin (TSLP) is a cy-
tokine that was identified as a growth factor in
the supernatant of Z210R.1 thymic stromal
cells that could support the development of
immature NAG8/7 B cells to the B220
 
 
 
/
IgM
 
 
 
 stage (1). The TSLP receptor complex is
a heterodimer that is composed of the IL-7
receptor 
 
 
 
 chain (IL-7R
 
 
 
) and a specific sub-
unit, TSLPR (2, 3). TSLPR is most similar to
the common cytokine receptor 
 
 
 
 chain (
 
 
 
c
 
), a
protein that is a critical component of the re-
ceptors for IL-2, -4, -7, -9, -15, and -21 (4).
TSLPR is expressed in many tissues, including
liver, brain, testis, bone marrow, spleen, and
thymus (2, 3, 5). Although TSLP shares some
actions with IL-7 (6, 7) and mediates the activa-
tion of Stat5 proteins (8), there also is evidence
for distinctive/nonredundant actions (9). TSLPR
KO mice have normal lymphocyte numbers,
but TSLPR/
 
 
 
c
 
 double KO mice display a greater
defect than do 
 
 
 
c
 
 KO mice, which indicates
that TSLP contributes to lymphopoiesis inde-
pendent of the contributions of IL-7 (10).
Correspondingly, injection of TSLP into 
 
 
 
c
 
 KO
mice induces the expansion of T and B cells
in vivo. TSLP enhances anti–CD3
 
 
 
-induced
proliferation and survival of CD4
 
 
 
, but not
CD8
 
 
 
, single positive thymocytes and peripheral
T cells in vitro, whereas IL-7 enhances the ex-
pansion of CD4
 
 
 
 and CD8
 
 
 
 T cells (10). More-
over, in adoptive transfer experiments, CD4
 
 
 
T cells from TSLPR KO mice expand less effi-
ciently than do WT CD4
 
 
 
 T cells in irradiated
hosts, whereas CD8
 
 
 
 T cell expansion is not
altered. Thus, murine TSLP has actions that
are related to T and B cell lymphopoiesis (10).
Human TSLP can induce naive CD4
 
 
 
 T
cells to generate the proallergic Th2 cytokines,
IL-4, -5, and -13, while inhibiting the produc-
tion of IL-10 and IFN-
 
 
 
 (11); however, this
effect was an indirect effect of TSLP on DCs,
rather than a direct effect on CD4
 
 
 
 T cells.
Human DCs that are treated with TSLP also
contribute to CD4
 
 
 
 T cell homeostasis (12).
Furthermore, TSLP-activated DCs induce the
differentiation of naive human CD8
 
 
 
 T cells into
effectors that exhibit cytolytic activity and pro-
duce IL-5 and -13 (13). These reports suggested
that human TSLP modulates immune function
through activating DCs, but it was suggested that
murine TSLP does not activate DCs (11).
We further investigate the role of murine
TSLP in regulating the immune response. Our
results indicate that TSLP enhances antigen-
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driven expansion of naive CD4
 
 
 
 T cells, but also can augment
the activity of DCs. Moreover, we also found that TSLPR
KO mice exhibit a markedly defective inflammatory lung re-
sponse to inhaled antigen, which suggests an important role
for TSLP in the development of this inflammatory response.
 
RESULTS
TSLP enhances proliferation of naive CD4
 
 
 
 T cells 
and generation of effector cells
 
Originally, murine TSLP was identified as a B cell growth
factor (1, 6, 14), and subsequently was shown to act on
CD4
 
 
 
CD8
 
 
 
 double negative thymocytes in synergy with
IL-1 (5). Subsequent work revealed that human TSLP can
regulate CD4
 
 
 
 T cell function and homeostasis, in part by
the activation of DCs (11, 12), and that murine TSLP plays
an important role in promoting TCR-mediated CD4
 
 
 
 T
cell homeostasis (10). To better understand the function of
TSLP in immune responses and to clarify the CD4
 
 
 
 T cell
populations on which it acts, we examined its effect on naive
(CD62L
 
 
 
CD44
 
low
 
), central memory (CD62L
 
 
 
CD44
 
hi
 
), and
effector memory (CD62L
 
 
 
CD44
 
 
 
) CD4
 
 
 
 T cell popula-
tions. TSLP significantly
 
 
 
enhanced anti-CD3–induced pro-
liferation of naive CD4
 
 
 
 T cells from BALB/c mice, but had
little effect on the expansion of memory phenotype CD4
 
 
 
 T
cells (Fig. 1 A).
To analyze the role of TSLP in vivo, we crossed TSLPR
KO mice to DO11.10 TCR transgenic (Tg) mice and ana-
lyzed TCR transgenic progeny that expressed (DO11.10/
Figure 1. TSLP promotes the proliferation of naive CD4  
T cells. (A) Purified naive (CD4 CD62L CD44 ), central memory 
(CD4 CD62L CD44 ), and effector memory (CD4 CD62L CD44 ) T cells 
from WT BALB/c mice were activated for 48 h with 2  g/ml anti-CD3 with 
or without 100 ng/ml TSLP and then pulsed with [3H]thymidine for 16 h. 
TSLP significantly increased the proliferation of naive CD4  T cells (P   0.01; 
top panel) but did not significantly affect memory CD4  T cell proliferation 
(middle and bottom panels). (B) Defective CD69 induction in TSLPR KO mice. 
WT mice, and TSLPR KO mice expressing the DO11.10 transgene were injected 
i.p. with OVA and aluminum hydroxide (ALUM) and analyzed the next day. 
(C) Decreased antigen-induced CD4  T cell proliferation in TSLPR KO mice. 
CD4  T cells from DO11.10/WT and TSLPR KO mice were labeled with CFSE 
and transferred to WT hosts that were immunized with OVA the next day. 
On day 5, KJ1-26  DO11.10/TSLPR KO cells had slower proliferation (mean 
fluorescence intensity (MFI)   267 and percent gated 54%) than did 
DO11.10/WT cells (MFI   12 and percent gated 98%) (cells from 7 out of 10 
TSLPR KO mice showed a slower rate of CFSE loss than WT cells, whereas 
cells from 3 out of 10 did not). (D–F) WT and TSLPR KO mice (not expressing 
the DO11.10 transgene) were immunized with OVA (200  g) and ALUM. 
Animals were killed on day 12 (D) or 60 (E) and splenocytes were cultured 
with OVA (0, 10, 50, and 200  g/ml). Splenocytes from TSLPR KO mice dis-
played significantly lower proliferation in response to secondary encounter 
with antigen at all concentrations tested (P   0.05 for all). (F) CD4  T cells 
purified from mice 60 d after immunization were incubated with APCs (sple-
nocytes that were depleted of T and NK cells) in the presence of different 
doses of OVA. CD4  T cells from TSLPR KO mice displayed significantly lower 
proliferation in response to the OVA (200  g/ml) in vitro (P   0.01) than did 
CD4  T cells from WT mice. Shown are means   SEM for five experiments. 
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WT) or lacked (DO11.10/TSLPR KO) the TSLPR gene.
Splenic CD4
 
 
 
 T cells from these mice expressed little, if any,
CD69, an early T cell activation marker (Fig. 1 B, top). In-
jection of mice with OVA significantly induced CD69 on
DO11.10/WT CD4
 
 
 
 T cells, but not on DO11.10/TSLPR
KO CD4
 
 
 
 T cells (Fig. 1 B, bottom). This suggests that
TSLP signaling is needed for the normal early activation of
naive CD4
 
 
 
 T cells by antigen in vivo, although a develop-
mental defect in the TSLPR KO mice is also possible. We
next examined the ability of DO11.10/WT and TSLPR KO
splenic T cells to proliferate in vivo by labeling them with
(5,6-carboxyfluorescein diacetate-succinimidyl ester (CFSE)
and transferring them to WT hosts that were immunized the
next day. An examination of KJ1-26
 
 
 
 T cells at day 5
showed that TSLPR KO cells proliferated—as evidenced by
the CFSE dilution—but at a slower rate than WT cells (Fig.
1 C), which indicated a role for TSLP in the expansion of
CD4
 
 
 
 T cells.
We next examined the role of TSLP in TCR-driven
generation of memory T cells from naive CD4
 
 
 
 T cells. WT
and TSLPR KO mice on a BALB/c WT background (i.e.,
not expressing the DO11.10 transgene) were immunized
with OVA. As evaluated by an in vitro antigen recall assay,
splenocytes that were isolated from TSLPR KO mice 12 or
60 d after immunization had a lower proliferative response
to secondary exposure to the antigen than did splenocytes
from WT mice (Fig. 1, D and E). We next isolated CD4
 
 
 
 T
cells 60 d after immunization and cultured these cells with
APCs at a 1:1 ratio in the presence of OVA. CD4
 
 
 
 T cells
from TSLPR KO mice showed much weaker proliferation
in response to secondary antigen exposure than did cells
from WT littermates (Fig. 1 F). These results suggest that
TSLP is involved primarily in antigen-driven activation of
naive CD4
 
 
 
 T cells and its absence substantially diminishes
the generation of memory T cells.
 
TSLPR plays a role in the activation of DCs in mice
 
We next sought to clarify the effect of TSLP on the contri-
bution of APCs to the CD4
 
 
 
 T cell expansion that occurs in
response to secondary stimulation in vitro. WT and TSLPR
KO mice were immunized with OVA, killed at day 60, and
splenic CD4
 
 
 
 T cells were purified and incubated at a 1:1
ratio with APCs in the presence of OVA. WT CD4
 
 
 
 T cells
cultured with WT APCs proliferated the most. Replace-
ment of WT APCs with TSLPR KO APCs mildly, but sig-
nificantly, reduced CD4
 
 
 
 T cell proliferation (Fig. 2 A).
TSLPR KO CD4
 
 
 
 T cells showed the weakest proliferative
response to antigen; this defect could not be corrected by in-
Figure 2. TSLP activates murine DCs. (A) In vitro antigen recall response. 
CD4  T cells and APCs from immunized WT and TSLPR KO mice were cultured 
with 200  g/ml of OVA for 48 h and then pulsed with [3H]thymidine. 
Shown are means   SEM for seven experiments. (B) Splenic CD11c  cells 
were sorted from the spleens of WT BALB/c animals and incubated overnight 
with media, TSLP alone, 5  g/ml of OVA323–339 peptide, or with OVA323–339 
peptide plus TSLP. TSLP treatment increased the surface levels of CD80, 
MHC class II, and CD86. Numbers represent mean fluorescent intensity. 
(C) Splenic DCs were incubated with 5  g/ml of OVA323–339 peptide alone 
or with TSLP before being washed, treated with mitomycin C, and cultured 
with purified CD4  T cells from DO11.10 RAG2    mice at a 1:10 ratio. 
Antigen presentation of DCs was enhanced significantly by TSLP treatment 
(P   0.005, shown are means   SEM for five experiments). (D) CD4  
T cells and DCs were purified from DO11.01/WT and DO11.10/TSLPR KO 
unmanipulated mice, and these were cultured together in the indicated 
combinations at a ratio of 1:10 DC/T cell, with 5  g/ml of OVA323–339 peptide, 
and [3H]thymidine incorporation determined at 48 h. Replacing WT APCs 
with TSLPR KO-derived DCs moderately, but significantly, reduced the 
antigen-driven proliferation of DO11.10 Tg/WT CD4  T cells (P   0.04). 
WT DCs provided no significant enhancement over the weak expansion of 
DO11.10/TSLPR KO CD4  T cells. Shown are means   SEM for seven 
experiments. (A and D) Asterisks indicate that the difference between WT 
CD4 /WT APCs or DCs and WT CD4 /KO APCs or DCs was statistically 
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troducing WT APCs (Fig. 2 A). Thus, TSLP is required for
the proliferation of normal CD4  T cells; the fact that prolif-
eration of WT CD4  T cells was decreased when TSLPR
KO APCs were used suggests that TSLP signaling plays a
role in promoting the optimal activity of APCs as well.
Human TSLP was shown to activate DCs, but surpris-
ingly it was suggested that murine TSLP did not show this
ability (11). In view of our findings above, we investigated
more formally the effect of murine TSLP on WT DCs. We
first confirmed that WT DCs express TSLPR mRNA using
RT-PCR (unpublished data). Moreover, the addition of
TSLP moderately increased the cell surface expression of
CD80, CD86, and MHC II (Fig. 2 B) on WT splenic
CD11c  DCs that were activated with OVA323–339 peptide
for 24 h. As compared with untreated DCs, TSLP-treated
DCs significantly enhanced OVA-mediated proliferation of
DO11.10 TCR transgenic CD4  T cells when the DCs and
T cells were incubated in a 1:10 ratio (Fig. 2 C); this clearly
demonstrated that mouse TSLP can activate DCs.
To examine further the effect of TSLP on the ability of
DCs to activate CD4  T cells, we isolated cells from naive
DO11.10/WT and DO11.10/TSLPR KO spleens, and cul-
tured DCs with CD4  T cells at a 1:10 ratio in the presence
of 5  g/ml of OVA323–339 peptide. As expected, DO11.10/
WT CD4  T cells that were cultured with WT DCs
showed substantial proliferation (Fig. 2 D). This was reduced
slightly, but significantly, when DO11.10/TSLPR KO DCs
were used (Fig. 2 D). The weak expansion seen when
TSLPR KO CD4  T cells were incubated with TSLPR KO
DCs was not enhanced significantly when WT DCs were
Figure 3. DCs activated with TSLP negatively regulate IFN-  
production by naive CD4  T cells. In panels A, B, C, and E, cells were 
cultured as indicated and subsequently challenged with PMA  ionomycin, 
and the intracellular levels of IFN-  and IL-4 were measured by intracellular 
staining. Numbers indicate the percent of cells in the indicated quadrant. 
(A) Naive and memory CD4  T cells ( 99% pure) were isolated from WT 
animals and treated with anti-CD3 with or without TSLP for 4 d. The addition 
of TSLP had no effect on the levels of IFN-  and IL-2 that were produced 
by CD4  T cells. (B) Purified CD4  T cells were activated with anti-CD3/
anti-CD28 under Th1 (IL-12 and anti–IL-4) or Th2 (IL-4 and anti–IFN- ) 
polarizing conditions with or without TSLP. IL-2 was added on day 2, and 
cells were allowed to grow for 1 wk. TSLP did not affect the IFN-  or IL-4 
production by these polarized cells. (C) Sorted splenic CD11c  DCs were 
incubated with 5  g/ml of OVA323–339 peptide alone or with TSLP before 
being washed, treated with mitomycin C, and cultured with purified CD4  
T cells from DO11.10 RAG2    mice at a 1:10 ratio from nonimmunized 
animals. TSLP-treated DCs reduced the levels of IFN-  production by 
KJ1-26 CD4  T cells, whereas the levels of IL-4 were not affected. (D) No 
significant difference was observed in the levels of IL-12 (p35) mRNA 
examined by RT-PCR in CD11c  DCs that were incubated overnight with 
5  g/ml of OVA323–339 peptide alone or with TSLP. (E) Total splenocytes 
from DO11.10/WT and DO11.10/TSLPRKO mice were cultured for 4 d with 
5  g/ml of OVA323–339 peptide before being activated with PMA  ionomycin 
for 5 h. KJ1-26  TSLPR KO T cells produced more IFN-  than did DO11.10/WT 
cells. (F) RNA was extracted from DO11.10/WT and DO11.10/TSLPRKO total 
splenocytes that were cultured for 4 d with 5  g/ml of OVA323–339 peptide. 
RT-PCR revealed significantly lower levels of IL-4 mRNA in the spleens of 
TSLPR KO mice; asterisk indicates that the value was significantly lower 
(P   0.05). The experiment was done four times with one or two mice in 
each experimental group in each experiment.JEM VOL. 202, September 19, 2005 833
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used. These results indicate that TSLP activates murine DCs,
but that the presence of TSLPR on CD4  T cells is more
vital than its presence on DCs for optimal proliferation in re-
sponse to the OVA323–339 peptide; this is consistent with the
results shown in Fig. 2 A.
TSLP-treated DCs reduce IFN-  production by CD4  T cells
Because TSLPR enhances naive CD4  T cell proliferation,
we examined if TSLP could influence TCR-induced cyto-
kine production by these cells. Purified naive CD4 CD62L 
CD44low and effector memory CD4 CD62L CD44hi
splenic T cells from WT BALB/c mice were activated with
anti-CD3 in the presence or absence of TSLP. On day 4,
cells were stimulated with PMA plus ionomycin for 5 h, and
intracellular levels of IFN-  and IL-4 were determined.
TSLP did not affect the level of IFN-  or IL-4 in naive or
memory CD4  T cells under neutral conditions (Fig. 3 A)
or when cells were activated using Th1 (IL-12 plus anti–
IL-4) or Th2 (IL-4 plus anti–IFN- ) polarizing conditions
(Fig. 3 B).
We next examined whether TSLP could influence the
differentiation of CD4  T cells indirectly by its action on
DCs. Sorted WT splenic CD11c  DCs were preincubated
with OVA323–339 in the presence or absence of TSLP before
being washed and incubated with congenic DO11.10 Tg
CD4  T cells on a RAG2 /  background. Treatment of
DCs with TSLP plus OVA323–339 reduced the levels of IFN- 
production in KJ1-26 CD4  DO11.10 Tg T cells (Fig. 3
C), and levels of IL-12 were below the level of detection
sensitivity by ELISA (not depicted). Treatment of DCs with
OVA323–339 plus TSLP versus OVA323–339 alone did not re-
sult in a statistically significant change in IL-12 mRNA lev-
els (Fig. 3 D). We next examined the production of IFN- 
and IL-4 by TSLPR KO mice. Splenocytes from WT and
TSLPR KO mice expressing the DO11.10 transgene were
cultured in the presence of OVA323–339. After 4 d of culture,
KJ1-26 CD4  T cells from DO11.10/TSLPR KO mice
consistently produced more IFN-  than did the analogous
T cells from DO11.10/WT mice (Fig. 3 E). Changes in IL-4
production were difficult to evaluate by intracellular stain-
ing because levels were very low in WT mice (Fig. 3 E),
but RT-PCR indicated that significantly less IL-4 mRNA
was expressed by the DO11.10/TSLPR KO splenocytes.
These results suggest that TSLP can influence cytokine pro-
Figure 4. TSLPR KO mice fail to mount an inflammatory response. 
(A–D) Periodic acid-Schiff–stained lung tissue sections of BALB/c WT and 
TSLPR KO mice that were sensitized (i.p.) and challenged (i.t. and i.n.) with 
OVA or PBS (i.p.). There were no obvious differences in the lung morphology 
between WT (A) and TSLPR KO (C) animals that were exposed to PBS. WT 
mice that received OVA displayed perivascular inflammation, peribronchiolar 
cuffing, and goblet cell hyperplasia (B), whereas TSLPR KO mice that were 
treated with OVA showed no obvious inflammation (D). (E) WT and TSLPR 
KO animals treated as shown above were tested for their airway hypersen-
sitivity response using methacholine (0, 6, 12, 25, and 50 mg/ml). Unlike 
WT animals, TSLPR KO mice immunized and sensitized with OVA showed 
similar results to PBS control mice (six to seven animals per group, shown 
is one representative experiment out of three). *Statistical significance 
(P   0.05) between the indicated dose and the 0 mg/ml. (F) Splenocytes 
from immunized WT and TSLPR KO mice were cultured in vitro with 200 
 g/ml OVA for 3 d. Supernatants were examined for IFN-  and IL-4 levels. 
The levels of IL-4 were significantly lower in the TSLPR KO animals versus 
the WT animals, whereas no statistical significance was observed for IFN- . 
The experiment was done four times with four mice in each experimental 
group in each experiment. *Statistical significance (P   0.05).TSLP PLAYS A ROLE IN INFLAMMATORY RESPONSE | Al-Shami et al. 834
duction by CD4  T cells indirectly by modulating the ac-
tivity of DCs.
TSLPR KO mice fail to develop a lung inflammatory response 
to OVA antigen
Having identified the effects of TSLP ON CD4  T cell pro-
liferation and differentiation, we next wanted to evaluate its
importance in a pathophysiologic model system. Therefore,
we examined the ability of TSLPR KO mice to control
an inflammatory response, using an OVA-induced allergic
asthma model (15). WT and TSLPR KO (F4 BALB/c) mice
were immunized twice i.p. with OVA and challenged by in-
tratracheal (i.t.) and intranasal (i.n.) administration of OVA.
As expected (15, 16), WT mice receiving OVA had perivas-
cular inflammation, marked peribronchiole cuffing with in-
flammatory cells, as well as goblet cell hyperplasia (Fig. 4, A
versus B). These mice scored 3–3.5 out of 4 on the inflam-
mation scale (see Materials and methods), with greater infil-
tration of eosinophils and neutrophils (Table I) than control
animals. In sharp contrast, TSLPR KO mice treated with
OVA had profoundly fewer cellular infiltrates and little, if
any, goblet cell hyperplasia in the bronchi (Fig. 4, D versus
C), with very few inflammatory cells (Table I). There were
no obvious differences between control WT and TSLPR
KO mice that were treated with PBS (Fig. 4, C versus A,
top; Table I). Analogous to this increased inflammation, WT
mice that were immunized with OVA had significantly
greater airway hyperresponsiveness to the increasing doses of
methacholine, whereas immunized TSLPR KO mice did
not (Fig. 4 E). Moreover, cultured splenocytes from immu-
nized WT mice produced significantly higher levels of IL-4
than did splenocytes from TSLPR KO mice, with no signif-
icant differences in the total amount of IFN-  (Fig. 4 F).
Corresponding to their having a defective “allergic” re-
sponse, TSLPR KO mice also had significantly lower levels
of IgE and higher IgG2a than did WT mice (Fig. 5 A). Levels
of OVA-specific IgG1, IgG2b, and IgG3 were normal (Fig. 5
A). Furthermore, unlike WT mice, TSLPR KO mice that
were sensitized to OVA and subsequently challenged with
OVA did not show a statistically significant increase in IL-2,
-4, -5, -10, -13, and IFN-  mRNA as compared with PBS-
treated mice (Fig. 5 B). OVA-induced protein levels of IL-5
and -13 were decreased in the bronchoalveolar lavage (BAL)
fluid from TSLPR KO mice (Fig. 5 C). Levels of IL-4 in the
BAL were below sensitivity levels (unpublished data). OVA
induced an increase in IL-13 mRNA in the lungs of TSLPR
KO mice, but only to the level seen in PBS-treated WT con-
trols (Fig. 5 B). These mice also displayed a significant in-
crease in IL-12 mRNA (Fig. 5 B). Furthermore, as compared
with WT mice, the lungs of TSLPR KO mice that received
OVA had significantly lower levels of CCL11 (eotaxin),
CCL17 (TARC), and CXCL9 (Mig) (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20050199/DC1).
These results indicate that TSLP is required to mount an op-
timal pulmonary inflammatory response to OVA.
The greatly diminished inflammatory response in the
lungs of TSLPR KO mice may have resulted from decreased
activation of CD4  T cells and/or from a developmental de-
fect in the TSLPR KO lungs. To study further the basis for
the decreased inflammatory response in the lungs, WT mice
were immunized twice with OVA, and CD4  T cells were
isolated from spleen and LNs and were transferred (i.v.) into
similarly immunized TSLPR KO mice. These mice were
challenged with OVA by an i.t. and i.n. route. CD4  T cells
from WT and TSLPR KO mice were transferred similarly
into WT and TSLPR KO animals as positive and negative
controls, respectively. An examination of the lungs revealed
severe inflammation and infiltration of eosinophils and neu-
trophils in WT animals that received WT CD4  T cells
(scoring 3.5 out of 4) (Fig. 6 A, i and ii), whereas TSLPR
KO supplemented with TSLPR KO CD4  T cells showed
little, if any, inflammation (0–0.5 out of 4) (Fig. 6 A, iii and
iv). This was consistent with the results in Table I and Fig. 4.
TSLPR KO mice that received WT CD4  T cells de-
veloped goblet cell hyperplasia and peribronchiole cuffing,
mostly in the large airways, but with some in the medium
airways with infiltration of eosinophils and neutrophils (Fig.
6 A, v and vi); they scored 2.2 out of 4 (range, 1.5–2.75) on
the inflammation scale. Thus, the TSLPR KO host could
support, at least in part, an inflammatory response if WT
CD4  T cells were provided, with a concomitant significant
increase in the levels of IFN-  IL-4, -5, and -13 mRNA
Table I. Absence of TSLPR blocks the development of lung inflammation and infiltration of inflammatory cells
Analysis Score Monocytes Lymphocytes Neutrophils Eosinophils
Normal lungs
Normal lungs
High perivascular 
and peribronchial inflammation
Slight inflammation
%%%%
WT   PBS 0–1 87   4 13   40 0
KO   PBS 0–1 95   35    30 0
WT   OVA 3–3.5 42   2 21   3 16   42 1
KO   OVA 0.5–1.5 87   2 11   21    11    1
BALB/c WT and TSLPR KO mice were sensitized (i.p.) and challenged (i.t. and i.n.) with OVA or PBS (i.p.). Shown are levels of inflammation in the lungs observed in Fig. 4 by periodic 
acid-Schiff staining, as well as the distribution of infiltrating leukocytes in BAL. TSLPR KO mice that were challenged with OVA showed weak inflammation with much less 
infiltration of inflammatory cells than did WT animals. The increase in eosinophils and neutrophils was significant (P   0.0001). The experiment was done four times with two 
to four mice in each experimental group in each experiment.JEM VOL. 202, September 19, 2005 835
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(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20050199/DC1). Transferring primed CD4  T cells
from TSLPR KO to WT nonimmunized animals did not
lead to the development of inflammation in the lungs of the
host after i.t. and i.n. challenge (unpublished data). These re-
sults further confirm that TSLP is involved in the activation
of CD4  T cells and is consistent with a role for this cyto-
kine in the development of the inflammatory response.
Finally, we neutralized TSLP in the lungs of WT mice
using 100  g of Fc-TSLPR fusion protein or Ig (i.t. and i.n.),
4 h before OVA challenge. Although positive control mice
(OVA only; Fig. 6 B, i and ii) or mice that received control
Ig (Fig. 6 B, iii and iv) developed a moderate to severe level
of inflammation and goblet cell hyperplasia, and scored 2.6
on the inflammation scale (range 2–3.5 out of 4) (Fig. 6 B, i),
the introduction of Fc-TSLPR fusion consistently diminished
the inflammatory response, with lower cellular infiltration
and fewer goblet cells observed (score 1.6, range of 1–2.5)
(Fig. 6 B, v and vi). Negative control mice that received PBS
(Fig. 6 B, vii and viii) showed no inflammation.
DISCUSSION
The survival of effector T cells and their progression to a
memory state has been an area of active investigation (17,
18). The critical role of the IL-7/IL-7R  system has been
underscored by the phenotypes of IL-7 and IL-7R  KO
mice (19, 20) and humans with IL-7R –deficient SCID
(21). Thus, part of the phenotype in IL-7R –deficient mice
and humans presumably results from the inactivation of
TSLP signaling. Data have accumulated that TSLP-activated
human DCs can induce the expansion and activation of allo-
genic naive CD4  T cells to a central memory phenotype,
whereas murine TSLP contributes to the generation of
CD4  T cells and can rescue, in part, lymphopoiesis in  c-
deficient mice (10).
In this study, we discovered that TSLP preferentially en-
hances the proliferation and expansion of TCR-stimulated
naive phenotype CD4  T cells. Moreover, TSLP is impor-
tant for the transition of naive CD4  T cells into activated
effector cells. Although we cannot exclude a developmental
defect in TSLPR KO mice, our data suggest that the defect
in these mice may be due, at least in part, to weaker antigen-
driven activation. Specifically, TSLPR KO mice displayed
no apparent abnormalities in lymphocyte numbers and sub-
population distribution (10), but there was weaker activation
of TSLPR KO CD4  T cells after immunization. Neverthe-
less, TSLPR KO mice produced OVA-specific IgG1 and
IgG2b at similar levels to WT mice; this indicated that an ac-
tive immune response is taking place in these mice and ar-
gues against a global developmental defect.
Figure 5. TSLPR KO mice exhibit partially altered allergic/
inflammatory immunoglobulin and cytokine profiles in the lungs in 
OVA-treated mice. BALB/c WT and TSLPR KO mice were sensitized (i.p.) 
and challenged (i.t. and i.n.) with OVA or PBS (i.p.). (A) Sera were tested at 
the indicated dilutions and the levels of OVA-specific immunoglobulin in 
PBS- and OVA-treated mice. Antibody was captured with plate-bound 
ovalbumin (2  g/ml) and detected with biotinylated isotype-specific 
secondary antibodies. OVA-TSLPR KO mice displayed significantly less IgE 
and more IgG2a than did WT treated littermates. (B) Cytokine levels in the 
lungs as determined by RT-PCR. (C) Cytokines protein levels in BAL as 
determined by ELISA. The results are expressed as means   SEM for four 
experiments, two to four mice per group per experiment. (A and B) *P   0.05 
between PBS and OVA group of WT and PBS and OVA group of TSLPR 
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Memory phenotype CD4  T cells express TSLPR
mRNA (unpublished data), but showed no significant pro-
liferative response to TSLP. The decreased responsiveness of
splenocytes from immunized TSLPR KO mice—as com-
pared with WT animals—to secondary exposure to antigen
may be due to the weak initiation phase of the immuniza-
tion process, with fewer cells differentiating into effector and
memory cells. It seems that naive cells are poised to respond
to TSLP activation, whereas IL-7 seems to play a greater role
that is related to their differentiation into memory cells (18).
Murine DCs can promote the clonal-specific expansion
of naive CD4  T cells. We show that TSLP is involved in
this process, but that TSLPR is more important to CD4  T
cells than to DCs. Although TSLP had no direct effect on
the production of IFN-  and IL-4 by CD4  T cells under
neutral or polarizing conditions, TSLP-treated DCs dimin-
ished the production of IFN-  by CD4  T cells, and corre-
spondingly, more IFN-  and less IL-4 were produced by
DO11.10/TSLPR KO splenocytes than by DO11.10/WT
cells. Similarly, splenocytes from immunized WT animals
that were activated in vitro with OVA produced more IL-4
than did TSLPR KO cells. The lower number of effector
cells in the TSLPR KO mice that produced higher levels of
IFN-  could explain the lack of difference in the amount of
IFN-  that was present in these cultures. Thus, the greatest
effect of TSLP on DCs may be to augment the differentia-
tion and cytokine production, rather than affecting the pro-
liferation of naive CD4  T cells directly.
The greatly diminished inflammatory response that was
seen in the lungs of TSLPR KO mice that were challenged
with OVA underscores the importance of the TSLP/TSLPR
system in vivo. Although TSLP levels are increased in in-
flamed tonsils and in the skin of individuals with atopic der-
matitis (11, 12), the importance of TSLP for these responses
could not be assessed because no neutralization or knockout
methodology was used. An immune response was confirmed
in these mice by the presence of OVA-specific IgG1 and
IgG2b; IgG2a was increased but IgE was not, which indi-
cated a Th1-like phenotype in the absence of TSLP (22).
This could result from higher levels of IFN-  that are pro-
duced in the TSLPR KO CD4  T cells. Because IL-13 is a
mediator of asthma that affects eosinophilic infiltration, mu-
cus secretion, and airway hyperresponsiveness in the lungs
(23–25), the reduced IL-13 in the lungs of TSLPR KO mice
Figure 6. TSLP plays a role in the development of asthma. (A)TSLPR 
KO mice succeed in mounting an inflammatory response in the lung after 
receiving WT CD4  T cells. Donor and recipient mice (F4 BALB/c) were 
sensitized with OVA (i.p.). Recipient mice were challenged with OVA (i.t.)
4 h before receiving 8   106 CD4  T cells. CD4  T cells from WT donor 
were transferred to WT (positive control, i and ii) and TSLPR KO (test sub-
ject, panels iii and iv) mice, whereas CD4  T cells from TSLPR KO mice were 
given to TSLPR KO mice to act as negative control (v and vi). All mice were 
treated the next day with OVA (i.n.) and killed 24 h later. Shown are the 
periodic acid-Schiff staining of lung tissue sections. The WT positive 
control displayed perivascular inflammation, peribronchiolar cuffing, and 
goblet cell hyperplasia (i and ii), whereas TSLPR KO mice showed no signs 
of lung inflammation (iii and iv). However, TSLPR KO mice that were 
supplemented with CD4  T cells (v and vi) exhibited inflammatory cells 
infiltration combined with peribronchiolar cuffing, and goblet cell hyper-
plasia in the large and medium airways. (B) Lung sections stained with 
periodic acid-Schiff show the effect of blocking TSLP using Fc-TSLPR fusion 
protein on the lung inflammation in WT animals that were immunized and 
sensitized with OVA. Introducing Fc-TSLPR fusion protein 4 h before each 
of the i.t. and i.n. OVA reduced the levels of inflammation in these animals 
(v and vi, score 1.6 with a range of 1–2.5) compared with animals that 
were treated with Ig (iii and iv, score 2.6 and a range of 2–3.5). WT mice 
that were treated with OVA (i and ii) or PBS (vii and viii) acted as positive 
and negative controls, respectively. The difference was statistically significant 
(P   0.01). The experiment was done three times with two mice in each 
experimental group in each experiment.JEM VOL. 202, September 19, 2005 837
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might explain the absence of inflammation and IgE in these
animals. Similarly, the absence of inflammatory CD4  T
cells in the lungs could explain the lack of IL-5, and subse-
quently, the absence of eosinophils in affected tissues. The
absence of CCL11 and CCL17 in the lungs of TSLPR KO
mice that were challenged with OVA helps to explain the
absence of inflammation in these mice, because neutralizing
these chemokines can abrogate lung eosinophilia and airway
hypersensitivity response (26–28).
The transfer of WT CD4  T cells to TSLPR KO mice
had a profound effect on the ability of these mice to mount
an inflammatory response. TSLPR KO lungs showed goblet
cell hyperplasia and peribronchiole cuffing, accompanied by
the infiltration of inflammatory cells; this was consistent with
the increase in IFN-  and IL-4, -5, and -13. Thus, the lungs
of TSLPR KO mice are structurally normal, and the mi-
croenvironment within them can allow the development
of an inflammatory response when functional preactivated
CD4  T cells are available. However, the lower inflamma-
tion in these mice compared with WT animals might be ex-
plained by the fact that WT mice possess more CD4  T
cells, because only a fraction of the WT CD4  T cells that
were transferred to TSLPR KO animals is expected to be
OVA responsive. In addition, the high levels of IL-12 and
the absence of CCL11 and CCL17 in the lungs of TSLPR
KO animals activated with OVA might limit the inflamma-
tory response in these animals.
In conclusion, our results reveal that TSLP plays a key
role in promoting the proliferation of naive CD4  T cells.
Although DC activation by TSLP may contribute to this
process, CD4  T cells seem to be the more important target
for TSLP. TSLP had little, if any, direct effect on cytokine
production by CD4  T cells, but influenced IFN-  produc-
tion by way of actions on DCs. In view of the importance of
TSLP, we also investigated its role in an allergic inflamma-
tory model in vivo, and unexpectedly found profoundly re-
duced inflammation in the lungs of TSLPR KO mice. These
data indicate that TSLP signaling is crucial for generation of
an inflammatory reaction in the lung and establish TSLP as a
potential target for modulating inflammation, findings with
potentially important clinical implications as well.
MATERIALS AND METHODS
Mice. TSLPR KO mice have been described (10). DO11.10 transgenic Rag
2 /  mice on B10.D2 and BALB/c backgrounds (purchased from Taconic)
were crossed to TSLPR KO mice on F1 129/BL/6 or BALB/c (F4) genetic
backgrounds (29). WT BALB/c animals were from The Jackson Laboratory.
All experiments were performed under protocols approved by the National In-
stitute of Health Animal Use and Care Committee and followed the Using An-
imals in Intramural Research guidelines from the National Institutes of Health.
TSLP effect on naive versus memory CD4 T cells. CD4 CD62L 
CD44low (naive), CD4 CD62L CD44high (central memory), and CD4 
CD62L CD44high (effector memory) phenotype T cells were isolated by
cell sorting and were  99% pure. RNA was extracted from freshly sorted
cells using TRIzol (Invitrogen). Purified cells also were suspended at 2  
105 cells/well and activated with anti-CD3  (2  g/ml, BD Biosciences)
with or without TSLP (100 ng/ml; R&D Systems) for 48 h before being
pulsed with 1  Ci of [3H] thymidine (6.7 Ci/mmol, NEN Life Science
Products) for the final 16 h of culture.
Immunization and antigen-recall response. Mice were immunized
by i.p. injection of 200  g of OVA (Pierce Chemical Co.) in 100  l of PBS
that had been mixed with 100  l of aluminum hydroxide (ALUM) as adju-
vant and incubated at room temperature for 30 min before injection. Mice
were killed 12 or 60 d after immunization. For assessing an antigen recall re-
sponse, purified CD4  T cells (105 cells/well) were cultured with an equal
number of splenic APCs or total splenocytes (2   105 cells/well) that were
treated with mitomycin C (50  g/ml in PBS for 15 min at 37 C) and
washed three times. These cells were incubated in 96-well flat-bottom
plates for 48 h in RPMI 1640 medium containing 10% FBS, 2 mM L-glu-
tamine, and antibiotics, and with 0, 10, 50, or 200  g/ml of OVA. Wells
were pulsed with 1  Ci of [3H]thymidine (6.7 Ci/mmol, NEN Life Sci-
ence Products) for the final 16 h of culture. Where indicated, APCs in-
cluded B cells, macrophages, and DCs, after depleting CD4  T cells, CD8 
T cells, and NK cells by positive selection. WT and TSLPR KO mice that
expressed the DO11.10 transgene were treated with 100  g of OVA in 100
 l of PBS in 100  l ALUM and analyzed the next day.
DC function. TSLP was from R&D Systems and tested negative for en-
dotoxin by the limulus amebocyte lysate test (BioWhittaker). To examine
the effect of TSLP on murine DCs, total splenic CD11c  DCs were isolated
by sorting ( 99% purity) from BALB/c WT mice, and cultured for 24 h at
106 cells/ml with OVA323–339 peptide (5  g/ml; Bachem) with or without
TSLP (100 ng/ml). The cells were lysed in TRIzol for RNA isolation or
were washed, treated with mitomycin C (50  g/ml, Sigma-Aldrich),
washed three times, and incubated with DO11.10 RAG 2 /  CD4  T cells
at a 1:10 ratio. Cells were cultured for 48 h to allow measuring proliferation
using [3H] thymidine incorporation, or for 4 d to examine intracellular lev-
els of IFN-  and IL-4 secretion, as described below.
“Mix and match” experiments were performed using CD4  T cells
that were purified by positive selection using specific magnetic beads
(Miltenyi Biotec). CD4  T cells and CD11c  DCs were isolated by posi-
tive selection using labeled magnetic beads (Miltenyi Biotec) in the presence
of 1% Fc block (BD Biosciences). The resulting CD4  T cells were  90%
pure and DCs were  80% pure. They were incubated together (1:10 ratio)
at various combinations (e.g., WT CD4  T cells with WT or TSLPR KO
DCs and TSLPR KO CD4  T cells with WT or TSLPR KO DCs) as indi-
cated. All DCs were treated with mitomycin C before being incubated with
CD4  T cells. Wells were pulsed with 1  Ci of [3H]thymidine (6.7 Ci/
mmol, NEN Life Science Products) for the final 16 h before harvesting.
Flow cytometric analyses. Single-cell suspensions were prepared from
thymus and spleen. Cells were washed with FACS buffer (phosphate buff-
ered saline pH 7.4 containing 0.5% BSA and 0.02% sodium azide). 1 mil-
lion cells were treated with Fc-block for 15 min before being incubated
with the indicated fluorochrome-conjugated antibodies (all from BD Bio-
sciences) for 20 min. Cells were washed twice with FACS buffer and ana-
lyzed. All antibodies used were from BD Biosciences, except KJ1-26 mAb,
which was from Caltag Laboratories. All flow cytometric data presented are
representative of at least three experiments with similar results.
Culture under polarizing conditions. Purified CD4  T cells were acti-
vated with anti-CD3 (2  g/ml) and anti-CD28 (1  g/ml) and cultured in
conditions favoring Th1 (1 ng/ml IL-12 and 10  g/ml anti–IL-4) or Th2
(1 ng/ml IL-4 and 20  g/ml anti–IFN- ) in the presence or absence of
TSLP (100 ng/ml). IL-2 (100 U/ml) was added on day 2 and cells were al-
lowed to expand for 1 wk.
Intracellular staining for IFN-  and IL-4 levels. Cultured cells were
activated with PMA (10 ng/ml) and ionomycin (1  g/ml) (both from
Sigma-Aldrich) for 5 h in the presence of Golgi Block (BD Biosciences).
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the DO11.10-specific transgene with KJ1-26. Intracellular staining was per-
formed using Cytofix/Cytoperm kit, and anti–IFN-  and IL-4 (all from
BD Biosciences) according to the manufacturer’s instructions.
Sensitization and airway challenge to mice. OVA (100  g in 100  l
of PBS) was mixed with 100  l of Imject ALUM and 200  l was injected
i.p. on days 0 and 7 to sensitize mice. On day 13, mice were challenged i.t.
with 50  g of OVA in 30  l PBS. On day 14, 50  g of OVA in 25  l PBS
was administered i.n. Control mice were treated similarly with PBS instead
of OVA. On day 16, mice were killed, bled, and BAL was performed using
0.5 ml of PBS. Cells from BAL fluid were isolated by cytospin, and leuko-
cytes were identified by staining using Wright/Giemsa. Lungs were used for
extracting RNA or for generating tissue sections for microscopic analysis.
Lung tissue sections were stained with periodic acid-Schiff or Wright/Gi-
emsa (Volu-Sol, UT). Serum levels of OVA-specific immunoglobulin were
measured by ELISA (BD Biosciences). Inflammation was scored on a scale
of 0 to 4 as follows: (0) normal lungs, no goblet cell hyperplasia; (1) minor
perivascular inflammation around large blood vessels; (2) moderate perivas-
cular and peribronchial inflammation, minimal evidence of goblet cell hy-
perplasia; (3) increased perivascular and peribronchial inflammation with in-
creased goblet cell hyperplasia beginning in smaller airways; (4) severe
formation of perivascular, peribronchial, and interstitial inflammation as
well as goblet cell hyperplasia in small and large airways.
Airway hyperresponsiveness responses of WT and TSLPR KO mice
that were immunized and challenged with PBS and OVA were examined
by challenging the mice with methacholine at 0, 6, 12, 25, and 50 mg/ml of
PBS and measuring “enhanced pause” using whole body plethysmography
(Buxco Electronics) following the manufacturer’s instructions.
To test the effect of blocking TSLP on the development of inflamma-
tion in the lungs, presensitized WT BALB/c mice were treated i.t. and i.n.
with 100  g (25  l of PBS) of human Ig or Fc-TSLPR (R&D Systems)
(the extracellular domain of murine TRSLPR fused to human Fc fragment)
4 h before OVA challenge through the same route. Mice were analyzed as
above to determine degree of lung inflammation.
Adoptive transfer of CD4  T cells. WT and TSLPR KO mice that
were backcrossed to BALB/c background for four generations were desig-
nated as donors and recipients, and immunized by intraperitoneal injections
of OVA (100  g) in 100  l of PBS, which were mixed with equal volume
of ALUM, and 200  l was injected on days 0 and 7). On day 13, recipient
mice were sensitized i.t. with 50  g of OVA in 30  l PBS, followed 4 h
later by i.v. transfer of 8   106 CD4  T cells extracted from spleen and
lymph nodes of donor mice. On day 14, 50  g of OVA in 25  l PBS was
administered i.n. Mice were killed and analyzed the next day for signs of
lung inflammation, using the criteria presented described before.
To determine the ability of DO11.10/WT and TSLPR KO splenic
CD4  T cells to proliferate in vivo, these cells were isolated from spleens,
labeled with CFSE (5  M for 10 min at 37 C), and transferred (8   106
cells) to WT hosts that were immunized the next day with OVA (100  g)
in ALUM or PBS. On day 5, lymph nodes were extracted and cells were
stained with anti–KJ1-26 mAb.
Real-time PCR. RNA was extracted from single-cell suspensions or from
lung tissue using TRIzol (Invitrogen). RNA was reverse transcribed using the
RNA PCR gold kit (Applied Biosystems). Levels of IL-2, -4, -5, -10, and
-13; IFN- ; TSLP; CCL2; CCL7; CCL11; CCL17; CXCL9; CCL22; and
TSLPR mRNA relative to 18S rRNA were measured by RT-PCR using
“gene expression assays” ready-made primers from Applied Biosystems.
Online supplemental materials. Fig. S1 shows the amount of mRNA,
as determined by RT-PCR, of selected chemokines in the lungs of mice
tested in an asthma model. Fig. S2 shows, in an asthma model, the increase
in lung inflammatory cytokine levels in TSLPR KO mice into which WT
CD4 T cells were transferred adoptively. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050199/DC1.
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